0001519692-22-000008.txt : 20221028
0001519692-22-000008.hdr.sgml : 20221028
20221028162432
ACCESSION NUMBER: 0001519692-22-000008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221020
FILED AS OF DATE: 20221028
DATE AS OF CHANGE: 20221028
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Greenstein Leonard M.
CENTRAL INDEX KEY: 0001519692
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39614
FILM NUMBER: 221342271
MAIL ADDRESS:
STREET 1: 24562 BELGREEN PLACE
CITY: LAKE FOREST
STATE: CA
ZIP: 92630
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001819790
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 814717861
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: (949) 409-9820
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
4
1
wf-form4_166698865674038.xml
FORM 4
X0306
4
2022-10-20
0
0001819790
Tarsus Pharmaceuticals, Inc.
TARS
0001519692
Greenstein Leonard M.
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE
CA
92618
0
1
0
0
Chief Financial Officer
Common Stock
2022-10-20
4
S
0
4877
15.90
D
54412
D
Common Stock
2022-10-20
4
S
0
123
16.62
D
54289
D
The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022.
The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.49 to $16.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $16.58 to $16.77. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Leonard M. Greenstein
2022-10-28